Wavre, 31 May 2019.
I am delighted to announce the publication of the annual report 2018 of WELBIO, an inter-university life sciences research institute funded by the Walloon Region.
The objective of WELBIO is to nurture scientific excellence and maximize technology transfer in order to support economic development and attract venture capital in Wallonia. We act upstream of industrial innovation.
WELBIO investigators conduct innovative basic research in various domains such as cancer biology, neurobiology, immunology, metabolism or microbiology. Their scientific discoveries could lead to the development of new drugs, treatments or diagnostic tools (e.g. cancer, metabolic or inflammatory diseases, neurodegenerative disorders or antimicrobial resistance) as well as to biotechnological applications.
Over the past year, WELBIO investigators have confirmed their very high scientific level as well as their dedication towards technology transfer. Besides the numerous scientific publications, a first spin-off firm has been launched in Wallonia, patients will soon be treated based on WELBIO findings, Walloon companies partner with WELBIO scientists, patent applications have been filed and the first industrial revenue has been received.
Strategic fundamental research is a long term investment of clearly demonstrated efficacy. Wallonia needs it and is currently reaping the rewards of its initiative. I hope the next parliament term will be the opportunity to capitalize on our results and to roll out a stable and ambitious WELBIO.
The annual report is available in English and French.
Pierre Van Renterghem, General Manager of WELBIO.